GSK to Double Oncology Pipeline in Trials
GSK plans to nearly double its cancer medicines in clinical trials next year as part of efforts to rebuild its oncology pipeline. Executives note the portfolio could approach twenty phase three studies by 2027 following strategic acquisitions.
Xurve View
Insights:
Xurve View
GSK PLC-SPON ADR will nearly double its clinical-stage cancer medicines portfolio to about 30 assets next year, expanding early-stage oncology research. The United Kingdom drugmaker is accelerating its oncology expansion following a $10.6B acquisition in the United States earlier this year. CEO Luke Miels is scaling the oncology pipeline to offset looming patent cliffs for blockbuster HIV treatments.
